Difference between revisions of "Altretamine (Hexalen)"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Alkylating-like, exact mechanism unknown--can form covalent adducts with tissue macromolecules including DNA.<ref name="insert">[http://us.eisai.com/pdf_files/hexalen_pi.pdf Altretamine (Hexalen) package insert]</ref><ref>[http://hemonc.org/docs/ | + | Class/mechanism: Alkylating-like, exact mechanism unknown--can form covalent adducts with tissue macromolecules including DNA.<ref name="insert">[http://us.eisai.com/pdf_files/hexalen_pi.pdf Altretamine (Hexalen) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/altretamine.pdf Altretamine (Hexalen) package insert (locally hosted backup)]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 16:28, 29 November 2011
General information
Class/mechanism: Alkylating-like, exact mechanism unknown--can form covalent adducts with tissue macromolecules including DNA.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
Regimens
Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)